Skip to main content
Diagnostic Medical Systems logo

Diagnostic Medical Systems — Investor Relations & Filings

Ticker · ALDMS ISIN · FR0012202497 LEI · 969500RKTIGCNNIKIN19 PA Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2019-12-05 Capital/Financing Update
Country FR France
Listing PA ALDMS

About Diagnostic Medical Systems

https://www.dms.com/en/home/

Diagnostic Medical Systems (DMS) specializes in the development, design, and manufacturing of medical imaging systems. The company's core focus is on digital radiology and bone densitometry. Its product portfolio includes radiography and fluoroscopy systems, mobile x-ray units, surgical C-arms, and bone densitometers. DMS is engaged in developing next-generation imaging solutions aimed at improving patient care and personalized medicine. Key development projects include new mobile and surgical imaging equipment and an advanced range of bone densitometers for diagnosing and monitoring pathologies affecting bone mineral density.

Recent filings

Filing Released Lang Actions
Mise en place d'un financement d'un montant maximum de 4 M EUR par bons d'émission d'obligations remboursables en numéraire et/ou en actions DMS ou Hybrigenics
Capital/Financing Update Classification · 99% confidence The document is a press release dated 05/12/2019 announcing the establishment of a financing arrangement up to a maximum of €4 million through the issuance of debt instruments convertible into cash and/or shares (Bons and Obligations) reserved for a specific investor (IRIS). Key phrases like 'Mise en place d'un financement', 'bons d'émission d'obligations remboursables', and details about capital structure changes and dilution clearly indicate a corporate financing activity. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV).
2019-12-05 French
DMS Group et EHGO mettent fin au contrat de financement par émission d'ORNANE avec BSA attachés d'un montant maximum de 25 M EUR
Capital/Financing Update Classification · 98% confidence The document is a press release dated 05/12/2019 announcing that DMS Group and EHGO have mutually terminated a financing agreement involving ORNANE (convertible bonds) with attached warrants (BSA). The text details the termination of a financing line that was never utilized and includes commentary from the CEO regarding ongoing strategic discussions and facility expansion. This type of announcement, concerning the termination of a financing arrangement and related capital structure updates, fits best under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it specifically addresses a financing mechanism.
2019-12-05 French
DMS Group et Fujifilm Europe annoncent un nouvel accord pour la fabrication et la commercialisation de solutions de salles de radiologie
Regulatory Filings Classification · 100% confidence The document is a press release dated 02/12/2019 announcing a new agreement between DMS Group and Fujifilm Europe regarding the manufacturing and marketing of radiology solutions. It details a commercial partnership, quotes executives, and mentions a major commercial success (Vidi Group). This type of announcement, focusing on strategic business developments and partnerships rather than routine financial reporting (like 10-K, ER, or IR), typically falls under general corporate news or regulatory filings. Since it is a formal announcement of a significant business event, and it doesn't fit the specific definitions for financial reports, management changes, or capital actions, it is best classified as a general Regulatory Filing (RNS) or potentially a specific type of corporate announcement. Given the options, RNS serves as the best general category for non-standard, material corporate news releases that are not explicitly defined elsewhere. The length (4805 chars) is substantial enough that it is the report itself, not just an announcement of a report (ruling out RPA).
2019-12-02 French
Croissance de +27% du chiffre d'affaires à fin septembre 2019
Earnings Release Classification · 100% confidence The document is a press release dated 23/10/2019, titled 'Croissance de +27% du chiffre d'affaires à fin septembre 2019' (Revenue growth of +27% at the end of September 2019). It provides unaudited consolidated revenue figures for the first nine months of 2019 (9 mois 2019) compared to 2018, along with commentary on business segments and future outlook. This content structure—providing key financial highlights for a specific interim period (nine months)—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a full Interim Report (IR), but rather the initial announcement of the results. 9M 2019
2019-10-23 French
Hybrigenics, division biotech de DMS Group, met le cap sur les Etats-Unis !
Regulatory Filings Classification · 95% confidence The document is a press release dated 16/10/2019 announcing that Hybrigenics (a division of DMS Group) has obtained FDA 510(k) marketing authorization for its lipofilling medical devices. This is a significant business development and regulatory milestone announcement, not a periodic financial report (like 10-K or IR), a transcript (CT), or a formal shareholder communication (like DEF 14A or AGM-R). It details business strategy, market access (US), and future pipeline developments (prostate cancer, osteoarthritis). This type of announcement, which details specific operational or regulatory achievements outside of standard financial reporting cycles, best fits the general 'Regulatory Filings' (RNS) category as a catch-all for important, non-standard corporate news, or potentially 'Capital/Financing Update' (CAP) if it were related to fundraising, but here it is purely operational/regulatory success. Given the options, RNS is the most appropriate fallback for a major, non-financial regulatory achievement announcement that doesn't fit a more specific operational category like M&A (TAR) or Director Dealing (DIRS). However, since it is a major announcement about a regulatory approval opening a new market, it is a significant corporate event announcement. Since there is no specific category for 'Regulatory Approval Announcement', RNS serves as the best fit for a general regulatory/corporate news release.
2019-10-16 French
Finalisation de l'apport partiel d'actif du pôle DMS Biotech : DMS Group détient 80% du capital d'Hybrigenics - Naissance d'une société de biotechnologies dédiée à l'utilisation des cellules souches a
Share Issue/Capital Change Classification · 99% confidence The document details the finalization of a partial asset transfer (apport partiel d'actif) where DMS Group transferred its DMS Biotech division to Hybrigenics. This transaction involves the issuance of new shares, a change in ownership percentage (DMS Group now holds 80% of Hybrigenics), and subsequent changes in the board of directors of Hybrigenics. This type of corporate restructuring, involving asset transfer, share issuance, and governance changes, is a significant corporate action. It is not a standard periodic report (10-K, IR, ER) nor a simple announcement of a report (RPA). It relates directly to capital structure changes and corporate control. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it describes a major change in capital structure and corporate control resulting from the transaction. It is also related to M&A activity (TAR), but since it is an asset contribution rather than a full takeover bid, CAP is slightly more precise for the mechanics described.
2019-10-15 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.